EN
抗体药类似物
Research Grade Sotrovimab
All
TD-VK565076_1.jpg
TD-VK565076_2.jpg
  • CatalogTD-VK565076
  • ClonalitymAb
  • Application Research Grade Biosimilar
  • SynonymsVIR-7831,GSK4182136,S309,CAS:2423014-07-5
  • 规格
    1mg
  • 价格
    ¥询价
定制服务咨询

Research Grade Sotrovimab


Catalog No. TD-VK565076
Species reactivity SARS-CoV-2 (2019-nCoV)
Applications Research Grade Biosimilar
Host species Human
Isotype IgG1, kappa
Expression system Mammalian Cells
Clonality Monoclonal
Target Spike glycoprotein, S glycoprotein, E2, Peplomer protein, Spike protein S1, Spike protein S2, Spike protein S2', S, 2
Endotoxin level Please contact the lab for this information.
Purity >95% purity as determined by SDS-PAGE.
Purification Protein A/G, purified from cell culture supernatant.
Accession P0DTC2
Form Liquid
Storage buffer 0.01M PBS,pH7.4.
Stability and Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
Alternate Names VIR-7831,GSK4182136,S309,CAS:2423014-07-5
Background Sotrovimab (VIR 7831) is a human IgG1κ pan-sarbecovirus monoclonal antibody (mAb), neutralizes SARS-CoV-2, SARS-CoV-1, and multiple other sarbecoviruses. Sotrovimab is developed based on S309, exhibits a long half-life and great bioavailability in the respiratory mucosa. Sotrovimab could result in immune-mediated viral clearance and prevent progression of Covid-19 early in the course of disease.
Note For research use only. Not for use in clinical or therapeutic applications.

 

TD-VK565076_1.jpg
SDS-PAGE
 
SDS-PAGE for Research Grade Sotrovimab.
TD-VK565076_2.jpg
Bioactivity
 
Detects RBD in indirect ELISAs.